President Donald Trump’s proposed budget for fiscal year 2026 would reduce the NIH budget by nearly $18 billion.

The FDA has granted fast track designation to INX-315 for the treatment of CCNE1-amplified, platinum-resistant/refractory ovarian cancer.

In an interview, FDA Commissioner Marty Makary opened up about his first weeks on the job and his vision for the future.

Adding penpulimab to chemotherapy can improve progression-free survival for patients with recurrent or metastatic nasopharyngeal carcinoma, data suggest.

In reducing federal funding and downsizing federal health agencies, the Trump administration is impeding cancer research.

Induction chemotherapy followed by IMRT is noninferior to CCRT for locoregionally advanced nasopharyngeal carcinoma, data suggest.

The FDA has issued a complete response letter to Telix Pharmaceuticals regarding TLX101-CDx for the imaging of gliomas.

Tepylute is now supplied as a multiple-dose vial containing 100 mg of thiotepa in addition to the previously approved single-dose vial containing 15 mg.

Tumor-infiltrating clonal hematopoiesis was associated with a greater risk of recurrence or death in patients with non-small-cell lung cancer.

Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.

The US nursing workforce remains under immense pressure due to stress, burnout, and persistent short staffing, according to a report.

Using both liquid and tissue biopsies to guide targeted treatment may improve outcomes in patients with solid tumor malignancies.